New Progress Made in China’s Treatment of COVID-19

Updated: Nov 23, 2021 04-15-2020

The Troika composed by Carrimycin, Chloroquine phosphate, and Favipiravir are expected to be promoted globally

At the press conference of the Joint Prevention and Control Mechanism of the State Council held at 15:00 on April 14th, relevant officials from the Ministry of Science and Technology of the PRC, the National Administration of Traditional Chinese Medicine, and the National Medical Products Administration answered questions raised by medias about progress in R&D on drugs and vaccines against COVID-19, etc.

When interviewed, the spokesperson at the conference pointed out that during this epidemic, a basic pattern of the main drugs had been formed at the moment through scientific research with “curable” as the main goal; a series of progress had been achieved in the development of new clinical treatment technologies, and the scientific research team was still actively promoting the deployment and research process of a new round of projects. In the future, the advancement of clinical research on drugs such as Carrimycin will be accelerated, aiming to realize more achievements faster for epidemic prevention and control.

Named twice, the clinical trials of Carrimycin, “drive into the fast lane”

Carrimycin was mentioned by name twice at this press conference. It is understood that Carrimycin is the world’s first class 1 new drug developed by using synthetic biology technology with independent Chinese intellectual property. The currently known clinical trial information shows that Carrimycin can remove the Corona Virus from the human body promptly and effectively, improve clinical symptoms and lung inflammation significantly, and is extremely safe compared to other drugs. Especially for severe and critically ill patients, virus recovery and patients with failed antiviral therapy, it has obvious effect without obvious adverse reactions.

The relevant person in charge of the Shenyang Tonglian Group pointed out in an interview that at present, the clinical trial of Carrimycin for the treatment of COVID-19 had entered the final stage. That “Accelerating the advancement of clinical research on Carrimycin” at this press conference will drive the development the clinical trial of Carrimycin into the fast lane. The relevant person pointed out the phased research outcomes of Carrimycin in the treatment of COVID-19 was expected to be officially disclosed within the next 1 to 2 weeks.

Research results of the constantly improved “China Plan” are expected to be promoted across the globe

In the research on drugs related to the COVID-19, the Chinese scientific research teams, always adhering to the basic idea of “finding innovative ways to usage of old drugs”, further clarified drugs with potential therapeutic effects based on rigorous vitro research and mechanism research.

The progress in clinical research and application of anti-epidemic drugs made by China has drawn the attention of the world successively. China has conducted exchanges and academic discussions with more than 140 countries and regions around the world in terms of anti-epidemic medicine products and scientific research results.

“The R&D of drugs against COVID-19 is a rapidly emerging research pattern which embodies the wisdom of the world and all mankind.” Sun Yanrong, Deputy Director of the Biological Center of the Biological Center of the Ministry of Science and Technology of PRC pointed out that chloroquine phosphate was invented by German scientists 80 years ago, favipiravir was invented by Japanese scientists 20 years ago and the Carrimycin which we are working on was invented by Chinese scientists 30 years ago. It indicates that only by gathering wisdom of mankind and the world can we realize better prevent and control over the severe epidemic spreading of the world.

At present, the scientific research PR team is actively expanding international cooperation channels, advancing the initiation or participation of international multi-center clinical research, and continuously improving the China Plan by gathering global wisdom to jointly fight the epidemic.

Chloroquine phosphate, favipiravir, and Carrimycin manufactured intelligently by china with sound feedback from clinical trials, may form a Troika, which is expected to be comprehensively promoted in the “battlefield” of the global fight against COVID-19.

Editor: Tian Shiyuan_sy98

46 views0 comments